Inclusion Criteria:  Woman or man, aged of 18 to 65 years; In good general health as evidenced by medical history and physical examination;  Having at least 3 episodes of sleep disorders per week including one or more of the following:  difficulty falling asleep or difficulty staying asleep or poor quality sleep Waking up earlier than desired The insufficient sleep duration and quality is coupled with a feeling of general fatigue; Sleep disorder last for more than 1 month; Presenting moderate to severe sleep disorder in the past month (ISI ≥ 15); With anxiety resulting in a HAM-A score > 8 and < 25;  For women of childbearing age (women of childbearing potential, pre-menopausal or having postmenopausal amenorrhea of less than 12 months, and women who have not undergone surgical sterilization):  Negative blood pregnancy test Acceptance to use an effective method of contraception, established for at least 1 month, and throughout the duration of the study; Fluent French speaking; Provision of signed and dated informed consent form; Stated willingness to comply with all study procedures and availability for the duration of the study.  Exclusion Criteria:  A score > 10 on the ESS scale (that would correspond to serious hypersomnia); Sleep disorders secondary to another health problem (sleep apnea syndrome, narcolepsy-cataplexy, idiopathic hypersomnia, restless legs syndrome, chronic pain syndrome, ...) or an environmental factor (noise, light ...) or socio-professional (shift work, young child at home, people who are often jet lagged,… ); Severe psychiatric disorder or disease within 6 months before inclusion (depression, bipolar disorder, severe anxiety, psychosis, schizophrenic disorders, dementia,…) or a severe neurologic trouble (Alzheimer's, autism, Parkinson's disease, …); Subjects presenting severe gastro-intestinal, hepatic, respiratory, kidney or cardiovascular disorder or severe infection (e.g. HIV, hepatitis, …); Acute or chronic somatic pathologies which can interfere with sleep: kidney cancer, etc.; Subjects with pre-menstrual syndrome or myasthenia gravis; Subjects who drink more than 2 glasses of alcohol per day (> 20g of alcohol per day) or with exaggerated consumption of theine (≥ 1l per day) and caffeine-rich (≥ 800ml per day) beverages and energy drink (≥ 330ml per day); Smoker; Subject consuming drugs and/or with historical drug addiction; Under psychotropic treatment within the last month before screening (neuroleptic, anxiolytic, antidepressant, hypnotic, sedative, …) or under current medication treatment which may alter the waking state (for example: cortisone, dopamine, amphetamine, antihistamines, beta-blockers, certain cough syrups, .…); Volunteer with suicidal risk according to the investigator; Under phytotherapy treatment or food supplement for sleep disorders within the last month before screening; Volunteer presenting current infection and/or fever; Volunteer with medical history of stroke or head trauma; Pregnant or lactating woman; Known allergy or intolerance to one product component (valerian, eschscholtzia or excipients); Subjects having participated to another clinical trial (with an investigational product) one month before the inclusion; Subjects that present alterations of their cognitive functions that will interfere with the comprehension of the study and procedures and/or with the completion of questionnaires; Vulnerable patient (deprived of liberty by judicial or administrative decision, under guardianship, curatorship or safeguard of justice, …); Pharmacological resistance to common hypnotic/sedative drugs; Allergy/intolerance to the actimeter straps; Recent (< 1 month before the inclusion) change in lifestyle (food, body weight > 5kg, sport).